Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329858 | 0.96 | SIGMAR1 (0.57) | SIGMAR1NPSR1IDO1POLBCTSK | |
| SCHEMBL4961185 | 0.92 | SIGMAR1 (0.62) | SIGMAR1NPSR1IDO1POLBMMP8 | |
| SCHEMBL22102023 | 0.90 | NPSR1 (0.61) | SIGMAR1NPSR1IDO1POLBMMP8 | |
| SCHEMBL5468072 | 0.90 | NPSR1 (0.61) | SIGMAR1NPSR1IDO1POLBMMP8 | |
| SCHEMBL8399561 | 0.90 | IDO1 (0.55) | SIGMAR1NPSR1IDO1POLBCTSK | |
| SCHEMBL13192909 | 0.89 | NPSR1 (0.55) | SIGMAR1NPSR1IDO1POLBCTSK | |
| SCHEMBL8478778 | 0.89 | SIGMAR1 (0.53) | SIGMAR1NPSR1IDO1POLBCTSK | |
| SCHEMBL4898925 | 0.89 | NPSR1 (0.55) | SIGMAR1NPSR1IDO1POLBCTSK | |
| SCHEMBL4583683 | 0.87 | POLB (0.65) | SIGMAR1NPSR1IDO1POLBCTSK | |
| SCHEMBL1587057 | 0.86 | GLA (0.50) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | VHL, MDM2, NEDD4 | SIGMAR1 2478/4885NPSR1 2958/4885IDO1 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.